| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDR1 |
| Uniprot No | P51861 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-262aa |
| 氨基酸序列 | MAWLEDVDFLEDVPLLEDIPLLEDVPLLEDVPLLEDTSRLEDINLMEDMALLEDVDLLEDTDFLEDLDFSEAMDLREDKDFLEDMDSLEDMALLEDVDLLEDTDFLEDPDFLEAIDLREDKDFLEDMDSLEDLEAIGRCGFSGRHGFFGRRRFSGRPKLSGRLGLLGRRGFSGRLGGYWKTWIFWKTWIFWKTWIFRKTYIGWKTWIFSGRCGLTGRPGFGGRRRFFWKTLTDWKTWISFWKTLIDWKTWISFWKTLIDWKI |
| 预测分子量 | 32.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为与CDR1重组蛋白相关的参考文献示例(注：CDR1通常指抗体的互补决定区，部分文献可能涉及重组抗体或单链抗体研究)：
1. **文献名称**: "Expression and functional characterization of a single-chain antibody fragment directed against CDR1 of human immunoglobulin"
**作者**: Li et al.
**摘要**: 研究构建了靶向人类免疫球蛋白CDR1区的单链抗体(scFv)，通过重组表达验证其与抗原结合活性，并证明其在体外诊断中的潜在应用价值。
2. **文献名称**: "CDR1-derived peptide recombinant protein induces antitumor immunity in a murine model"
**作者**: Zhang Y, Wang X, et al.
**摘要**: 利用CDR1区序列设计重组多肽疫苗，在小鼠模型中验证其通过激活T细胞免疫反应抑制肿瘤生长的效果，为肿瘤免疫治疗提供新策略。
3. **文献名称**: "Structural analysis of CDR1 in recombinant antibodies by X-ray crystallography"
**作者**: Smith J, Brown K.
**摘要**: 通过X射线晶体学解析含CDR1区的重组抗体结构，揭示其与抗原结合的构象变化机制，为抗体工程优化提供结构基础。
4. **文献名称**: "High-yield production of CDR1-engineered recombinant antibodies in E. coli for targeted therapy"
**作者**: Gupta R, Patel S.
**摘要**: 开发基于大肠杆菌表达系统的CDR1区重组抗体高效生产工艺，验证其在靶向药物递送中的稳定性和特异性，推动低成本抗体药物开发。
---
**注**：以上为模拟参考文献，实际研究中请通过数据库(如PubMed、Web of Science)检索具体文献。CDR1相关研究多集中于抗体工程、肿瘤免疫或感染性疾病领域，建议结合具体研究方向筛选文献。
CDR1 (Complementarity-Determining Region 1) recombinant protein is a biologically engineered molecule derived from the antigen-binding regions of antibodies, specifically the variable domains of immunoglobulin heavy or light chains. CDRs are hypervariable loops critical for antibody-antigen interactions, with CDR1 playing a key role in determining binding specificity and affinity. Recombinant CDR1 proteins are synthesized using genetic engineering techniques, where the DNA sequence encoding CDR1 is cloned into expression vectors and produced in host systems like *E. coli*, yeast, or mammalian cells.
The development of CDR1 recombinant proteins is driven by their therapeutic and diagnostic potential. In immunotherapy, they serve as components of engineered antibodies, bispecific antibodies, or chimeric antigen receptors (CARs) to enhance targeting precision in cancer or autoimmune diseases. Their small size and modularity also make them valuable tools for studying antigen-antibody interactions, epitope mapping, and structural biology.
Notably, CDR1-based proteins are explored in contexts beyond traditional antibody engineering. For example, CDR1 peptides from pathogenic autoantibodies have been investigated in rheumatoid arthritis and lupus to modulate immune responses. However, challenges persist in maintaining conformational stability and biological activity during large-scale production, as CDR1’s functionality often depends on proper folding and post-translational modifications.
Recent advances in computational modeling (e.g., AlphaFold) and high-throughput screening have accelerated the optimization of CDR1 recombinant variants, enabling tailored designs for specific applications. As personalized medicine and targeted therapies gain momentum, CDR1 recombinant proteins represent a versatile platform bridging antibody engineering, molecular diagnostics, and therapeutic development.
×
